V. Basil Hans,
- , Srinivas University, Mukka Mangalore, Karnataka, India
Abstract
Molecular biotechnology has advanced much beyond conventional DNA manipulation, into a phase characterised by precision, integration, and invention. This article examines the evolving domain of next-generation biotechnological instruments, encompassing gene editing technologies like CRISPR-Cas systems, synthetic biology, and RNA-based medicines. It shows how these new technologies are changing medicine by making treatments more personalised, making farming more productive by using genetically modified crops, and making industrial processes more environmentally friendly through bioengineering. The article also talks about how molecular biotechnology, artificial intelligence, and nanotechnology are coming together to speed up discoveries and push the limits of what is biologically feasible. There is also talk about ethical issues, regulatory problems, and the effects on society, which all point to the need for responsible innovation. In the end, this new era of molecular biotechnology holds the prospect of revolutionary solutions to global problems while changing how we may build and regulate living systems.
Keywords: Molecular Biotechnology, Editing Genes, Synthetic Biology , RNA Medicines ,Bioengineering
[This article belongs to International Journal of Molecular Biotechnological Research ]
References
1. Hoose A, Vellacott R, Storch M, and S. Freemont P. Technologies for DNA synthesis to bridge the gap in gene writing. 2023. ncbi.nlm.nih.gov
2. Dwivedi S, Purohit P, Misra R, Pareek P, and others. Diseases and Molecular Diagnostics: Advancing Towards Precision Medicine. 2017. ncbi.nlm.nih.gov
3. Gunn P, Walsh S, Roux C. The nucleic acid revolution is still going strong. Will forensic biology turn into forensic molecular biology? 2014. ncbi.nlm.nih.gov
4. F. Palazzo A, S. Kejiou N. Molecular Biology Not Based on Darwinism. 2022. ncbi.nlm.nih.gov
5. Zhang F, Nangreave J, Liu Y, Yan H. Structural DNA Nanotechnology: State of the Art and Future Perspective. 2014. ncbi.nlm.nih.gov
6. Reautschnig P, Vogel P, Stafforst T. The notorious R.N.A. in the spotlight – drug or target for the treatment of disease. 2016. ncbi.nlm.nih.gov
7. Zogg H, Singh R, Ro S. Current Advances in RNA Therapeutics for Human Diseases. 2022. ncbi.nlm.nih.gov
8. Grünberg R, Serrano L. Strategies for protein synthetic biology. 2010. ncbi.nlm.nih.gov
9. J. B, M. M. B, Chanda K. Evolutionary approaches in protein engineering towards biomaterial construction. 2019. ncbi.nlm.nih.gov
10. Collins L, Schönfeld B, Chen X. The epigenetics of non-coding RNA. 2011. (pages 49-61), edited by T. Tollefsbol and published by Academic Press
11. Rong D, Sun G, Wu F, Cheng Y et al. Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers. 2021. ncbi.nlm.nih.gov
12. Chen P, Sun Z, Wang J, Liu X et al. Portable nanopore-sequencing technology: Trends in development and applications. 2023. ncbi.nlm.nih.gov
13. Hayat Khan S. Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application. 2019. ncbi.nlm.nih.gov
14. C. Kaczmarek J, S. Kowalski P, G. Anderson D. Advances in the delivery of RNA therapeutics: from concept to clinical reality. 2017. ncbi.nlm.nih.gov
15. García-Granados R, García-Granados R, Alexis Lerma-Escalera J, Alexis Lerma-Escalera J et al. Metabolic Engineering and Synthetic Biology: Synergies, Future, and Challenges. 2019. Front. Bioeng. Biotechnol., 04 March 2019 Sec. Synthetic Biology Volume 7 – 2019 | https://doi.org/10.3389/fbioe.2019.00036
16. H. McArthur G, S. Fong S. Toward Engineering Synthetic Microbial Metabolism. 2010. ncbi.nlm.nih.gov
17. Lim J, Park C, Kim M, Kim H et al. Advances in single-cell omics and multiomics for high- resolution molecular profiling. 2024. ncbi.nlm.nih.gov
18. E. Dunn K. The Business of DNA Nanotechnology: Commercialization of Origami and Other Technologies. 2020. ncbi.nlm.nih.gov
19. D. Sindelar R. Genomics, Other “Omic” Technologies, Personalized Medicine, and Additional Biotechnology-Related Techniques. 2013. ncbi.nlm.nih.gov
20. Fadhli Hamdan M, Nurfadhlina Mohd Noor S, Abd-Aziz N, Pua TL et al. Green Revolution to Gene Revolution: Technological Advances in Agriculture to Feed the World. 2022. ncbi.nlm.nih.gov
21. K Varshney R, K Pandey M, Chitikineni A. Plant Genetics and Molecular Biology: An Introduction. 2018. edited by Rajeev K. Varshney, Manish K. Pandey, and Annapurna Chitikineni
22. Basyaruddin Abdul Rahman M. Haute couture: molecules and biocatalysts. 2010. Universiti Putra Malaysia Press Serdang • 2010 http://www.penerbit.upm.edu.my 23. Stalidzans E, Dace E. Sustainable metabolic engineering for sustainability optimisation of industrial biotechnology. 2021. ncbi.nlm.nih.gov
24. Ariff, Arbakariya (2009) Industrializing biotechnology: roles of fermentation and bioprocess technology. [Inaugural Lecture]
25. Lalor F, Fitzpatrick J, Sage C, Byrne E. Sustainability in the biopharmaceutical industry: Seeking a holistic perspective. Biotechnol Adv. 2019 Sep-Oct;37(5):698-707. doi: 10.1016/j.biotechadv.2019.03.015. Epub 2019 Mar
26. PMID: 30922993. 26. Schmidt‐Dannert C, Lopez‐Gallego F. A roadmap for biocatalysis – functional and spatial orchestration of enzyme cascades. 2016. ncbi.nlm.nih.gov
27. Quintal Gomes A, Soares H. New high-throughput technologies of post genome era: benefits and ethical issues. 2017. https://www.semanticscholar.org/
28. Asin-Garcia E, Robaey Z, F. C. Kampers L, A. P. Martins dos Santos V. Exploring the Impact of Tensions in Stakeholder Norms on Designing for Value Change: The Case of Biosafety in Industrial Biotechnology. 2023. ncbi.nlm.nih.gov
29. Trump B, Cummings C, Klasa K, Galaitsi S et al. Governing biotechnology to provide safety and security and address ethical, legal, and social implications. 2023. ncbi.nlm.nih.gov
30. Diggans J, Leproust E. Next Steps for Access to Safe, Secure DNA Synthesis. 2019. ncbi.nlm.nih.gov
31. Fullerton SM, Knerr S, Burke W. Finding a Place for Genomics in Health Disparities Research. 2012. ncbi.nlm.nih.gov
32. Séguin B, Hardy BJ, A. Singer P, S. Daar A. Genomic medicine and developing countries: creating a room of their own. 2008. ncbi.nlm.nih.gov
33. A McClellan K, Avard D, Simard J, M Knoppers B. Personalized medicine and access to health care: potential for inequitable access?. 2013. ncbi.nlm.nih.gov
34. Torres Vidal A, L. Medintz I, Bui H. DNA Microsystems for Biodiagnosis. 2020. ncbi.nlm.nih.gov
35. A. Bartley B, Beal J, R. Karr J, A. Strychalski E. Organizing genome engineering for the gigabase scale. 2020. ncbi.nlm.nih.gov
36. Currin A, Swainston N, S Dunstan M, J Jervis A et al. Highly multiplexed, fast and accurate nanopore sequencing for verification of synthetic DNA constructs and sequence libraries. 2019. ncbi.nlm.nih.gov
37. Hong K. BREAKTRHOUGH BIOTECHNOLOGIES: CAN THE FDA KEEP UP WITH THE SPEED OF SCIENCE?. 2012. Report of the Science Looking Forward Subcommittee PREPARED FOR FDA Science Board
38. M Jessop-Fabre M, Sonnenschein N. Improving Reproducibility in Synthetic Biology. 2019. ncbi.nlm.nih.gov
39. C. Schatz M. Biological data sciences in genome research. 2015. ncbi.nlm.nih.gov
International Journal of Molecular Biotechnological Research
| Volume | 04 | |
| Issue | 01 | |
| Received | 23/04/2026 | |
| Accepted | 24/04/2026 | |
| Published | 05/05/2026 | |
| Publication Time | 12 Days |